Inloggen
E-mail
Wachtwoord
Paswoord weergeven
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON
  1. Homepagina
  2. Aandelen
  3. Nederland
  4. Euronext Amsterdam
  5. Galapagos NV
  6. Nieuws
  7. Persberichten
    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
OverzichtKoersenGrafiekenNieuwsRatingenAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuwsAnalyse MarketScreener
Communiquťs de presse de la sociťtť GALAPAGOS NV
2015GALAPAGOS : and Gilead Announce Global Partnership to Develop Filgotinib for the..
BU
2015GALAPAGOS : Filgotinib meets primary endpoint in phase 2 study in patients with ..
GL
2015GALAPAGOS : increases share capital through warrant exercises
GL
2015GALAPAGOS : Invitation to the Special Shareholders' Meeting of Galapagos on 22 D..
PU
2015GALAPAGOS : Invitation to the Special Shareholders' Meeting of Galapagos on 22 D..
GL
2015GALAPAGOS : initiates Phase 1 First-in-Human study with GLPG1972, receives Ä3.5 ..
GL
2015GALAPAGOS : reports third quarter 2015 cash position of Ä374 M
GL
2015GALAPAGOS : builds on strong profile of filgotinib in 7 presentations at ACR 201..
GL
2015GALAPAGOS : Dr. Christine Mummery appointed to Galapagos' Board of Directors
PU
2015GALAPAGOS : Dr. Christine Mummery appointed to Galapagos' Board of Directors
GL
2015GALAPAGOS : advances triple combination therapy in cystic fibrosis
GL
2015GALAPAGOS : Positive safety and tolerability for novel potentiator GLPG1837
GL
2015GALAPAGOS : October 8, 2015 Galapagos to present promising findings in cystic fi..
PU
2015GALAPAGOS : October 2, 2015 Galapagos raises Ä1.2 million through warrant exerci..
PU
2015GALAPAGOS : raises Ä1.2 million through warrant exercises
GL
2015GALAPAGOS : to advance filgotinib to Phase 3 in rheumatoid arthritis
GL
2015GALAPAGOS : September 22, 2015 Galapagos presents promising pre-clinical and Pha..
PU
2015GALAPAGOS : presents promising pre-clinical and Phase 1 results with autotaxin i..
GL
2015GALAPAGOS : DARWIN 2 24-week monotherapy data in RA confirm previous results and..
GL
2015GALAPAGOS : August 6, 2015 Patient recruitment completed in FITZROY Phase 2 Croh..
PU
2015GALAPAGOS : Aug 5, 2015 Galapagos on track to deliver on pipeline in second half..
PU
2015GALAPAGOS : Patient recruitment completed in FITZROY Phase 2 Crohn's disease stu..
GL
2015GALAPAGOS : on track to deliver on pipeline in second half 2015
GL
2015GALAPAGOS : July 29, 2015 Galapagos' selective JAK1 inhibitor filgotinib meets k..
PU
2015GALAPAGOS : ' selective JAK1 inhibitor filgotinib meets key efficacy endpoints, ..
GL
2015GALAPAGOS : licenses Organoid Technology from the HUB foundation for use in cyst..
GL
2015GALAPAGOS : raises Ä4.4 million through warrant exercises
PU
2015GALAPAGOS : raises Ä4.4 million through warrant exercises
GL
2015GALAPAGOS : completes recruitment for ORIGIN Phase 2 trial with GLPG1205 in ulce..
GL
2015GALAPAGOS : AbbVie and Galapagos present cystic fibrosis corrector and potentiat..
GL
2015GALAPAGOS : DARWIN 1 and 2 studies have completed 24 weeks of treatment
GL
2015GALAPAGOS : May 26, 2015 Galapagos receives transparency notices
PU
2015GALAPAGOS : receives transparency notifications
GL
2015GALAPAGOS : May 19, 2015 Galapagos announces share capital increase
PU
2015GALAPAGOS : announces capital increase
GL
2015GALAPAGOS : announces closing of NASDAQ IPO
GL
2015GALAPAGOS : announces full exercise of underwriters' option to purchase addition..
PU
2015GALAPAGOS : announces full exercise of underwriters' option to purchase addition..
GL
2015GALAPAGOS : raises $275 million gross proceeds with NASDAQ IPO
GL
2015GALAPAGOS : announces size of global offering increased to $250 million
PU
2015GALAPAGOS : May 7, 2015 Johnson & Johnson Innovation – JJDC, Inc. indicate..
PU
2015GALAPAGOS : listed 10 years on Euronext Amsterdam and Brussels
GL
2015GALAPAGOS : announces launch of proposed global offering
GL
2015GALAPAGOS : creates new warrant plan
PU
2015GALAPAGOS : BNP Paribas notify of 4.8% shareholding in Galapagos
PU
2015GALAPAGOS : BNP Paribas notify of 4.8% shareholding in Galapagos
GL
2015GALAPAGOS : creates new warrant plan
GL
2015GALAPAGOS : Filgotinib as monotherapy also hits primary endpoint in DARWIN 2 tri..
GL
2015GALAPAGOS : April 15, 2015 Galapagos files registration statement in the United ..
PU
2015GALAPAGOS : files registration statement in the United States for a proposed glo..
GL
2015GALAPAGOS : April 14, 2015 Galapagos' JAK1 inhibitor filgotinib (GLPG0634) meets..
PU
2015GALAPAGOS : ' JAK1 inhibitor filgotinib (GLPG0634) meets primary and other key e..
GL
2015GALAPAGOS : raises Ä5.8 million through warrant exercises, Board and Executive C..
PU
2015GALAPAGOS : Publication of Annual Report 2014 and invitation to the Annual Share..
PU
2015GALAPAGOS : Publication of Annual Report 2014 and invitation to the Annual Share..
GL
2015Galapagos raises EU5.8 million through warrant exercises, Board and Executive..
GL
2015GALAPAGOS : raises Ä5.8 million through warrant exercises, Board and Executive C..
GL
2015GALAPAGOS : March 6, 2015 Galapagos to be included in Amsterdam Midcap Index Vie..
PU
2015GALAPAGOS : March 6, 2015 Galapagos reports 2014 financial results View English ..
PU
2015GALAPAGOS : March 17, 2015 Galapagos regains rights to GLPG1690, announces end o..
PU
2015GALAPAGOS : regains rights to GLPG1690, announces end of alliance with Janssen
GL
2015GALAPAGOS : to be included in Amsterdam Midcap Index
GL
2015GALAPAGOS : reports 2014 financial results
GL
2015GALAPAGOS : reports that the last patient in DARWIN 1 has completed 12 weeks of ..
GL
2015GALAPAGOS : reports positive Phase 1 results for GLPG1690
GL
2015Galapagos receives EU1.6 million IWT grant for hepatitis B program
GL
2015GALAPAGOS : receives Ä1.6 million IWT grant for hepatitis B program
GL
2015GALAPAGOS : BNP Paribas notify of 5.08% shareholding in Galapagos
GL
2015Galapagos receives EU2.5 million IWT grant for antibiotic research
GL
2015GALAPAGOS : receives Ä2.5 million IWT grant for antibiotic research
GL
2015GALAPAGOS : Delta Lloyd notify of 4.96% shareholding in Galapagos
GL
2015GALAPAGOS : Vicki Sato resigns from Galapagos Board
GL
2015GALAPAGOS : starts Phase 2 trial with GLPG1205 in ulcerative colitis patients
GL
2014Galapagos initiates first Phase 1 study in cystic fibrosis and will receive m..
GL
2014GALAPAGOS : initiates first Phase 1 study in cystic fibrosis and will receive mi..
GL
Vorig1  2  3  4  5   6  7Volgende
Volgende evenement op GALAPAGOS NV
22/09/21
Komende gebeurtenissen in de sector